Home/Pipeline/AAV Gene Therapy Platform Assets

AAV Gene Therapy Platform Assets

Cardiovascular Diseases (unspecified)

Pre-clinical (inferred)Active

Key Facts

Indication
Cardiovascular Diseases (unspecified)
Phase
Pre-clinical (inferred)
Status
Active
Company

About Theragene Pharmaceuticals

Theragene Pharmaceuticals is a clinical-stage biotech developing novel therapies in oncology and cardiology via two distinct platforms: an immunotherapy platform designed to enhance the body's anti-tumor response and an AAV gene therapy platform for cardiovascular diseases. Operating with a unique US-Asia development model, the company aims to leverage regional strengths to accelerate and de-risk its programs. Its strategy centers on advancing its internal pipeline while seeking licensing and co-development partnerships to bring safe, effective treatments to market.

View full company profile

Therapeutic Areas